Navigation Links
New TB Vaccine Passes Safety Trial
Date:4/8/2009

Experimental preparation was tested in people with latent infection,,

WEDNESDAY, April 8 (HealthDay News) -- An experimental tuberculosis vaccine called MVA85A proved safe in a small phase I clinical trial.

The study included 12 people with latent tuberculosis infection, which, when re-activated, can cause full-blown TB. It's believed that about a third of the world's population has this latent infection. The participants, who had no other complicating factors, such as hepatitis or HIV, were given the vaccine and then followed for a year.

The researchers concluded that the vaccine was safe, did not produce any immunopathology and was immunogenic in the patients. Some participants had side effects that included fever, headache, fatigue and mild concerns at the site of the vaccination.

The findings appear in the April 15 issue of the American Journal of Respiratory and Critical Care Medicine.

This study could be an important step forward in efforts to introduce a new vaccine to fight TB, according to the researchers, led by Dr. Helen McShane, of the University of Oxford in England. They noted that any new vaccine must be developed with latent TB infection in mind because it might decrease the effectiveness of new vaccines or worsen vaccine-related side effects.

"A more effective vaccine regimen than the currently available bacillus Calmette-Guerin would have a major impact on the global TB burden and, ultimately, will be the most efficient way to control this pandemic," the researchers wrote.

They noted that larger trials of the vaccine "are needed in TB endemic areas to assess the efficacy of this vaccine against the development of TB disease, but these results are very encouraging and justify the further development of this vaccine."

More information

The American Lung Association has more about

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
2. Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India
3. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
4. Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
5. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
6. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
7. Oral Yogurt Vaccine Could Blunt Ouch Factor
8. HPV Data May Aid Vaccines Effectiveness
9. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
10. HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market
11. TB vaccine developed at McMaster University in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New TB Vaccine Passes Safety Trial
(Date:5/28/2015)... Dr. Paul Vitenas, one of the nation’s ... new Houston Surgery Center he recently opened has received ... Surgery Facilities awarded this accreditation to Dr. Vitenas’ new ... Dr. Vitenas, the certificate was given to the surgery ... ambulatory surgery facility. This certification means the Houston Surgery ...
(Date:5/28/2015)... Beverly Hills, CA (PRWEB) May 28, 2015 ... a novel interactive keratoconus web application to ... Keratoconus has expanded in the last few years. This ... Even eye doctors are not aware of the nuances ... the Khanna Vision Institute, realized that websites can be ...
(Date:5/28/2015)... lifeIMAGE announced today that it ... by Cambia Health Solutions (Portland, Ore.), a ... care by creating a person-focused and economically sustainable system. ... exchanging medical imaging, will use this financing to expand ... of its network capabilities and implement the next phases ...
(Date:5/28/2015)... IL (PRWEB) May 28, 2015 Cancer ... program exhibited improvements in physical activity, fitness and quality ... Irwin of Yale Cancer Center and Jennifer Ligibel, MD, ... Women’s Cancers, Dana Farber Cancer Institute. The findings will ... Clinical Oncology (ASCO) Annual Meeting in Chicago. ...
(Date:5/28/2015)... May 28, 2015 Ask not what your ... things you can do with your racquet. With the launch ... Stefan Bojic, who brings his astonishing tricks and unique skill ... a series of videos, the trick artist playfully demonstrates how ... skills in a fun way, but also challenges tennis enthusiasts ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2
... This release is available in French . ... the American Urology Association (AUA) in Washington, DC demonstrates that ... for Benign Prostatic Hyperplasia (BPH) an enlargement of the ... conducted by researchers from the McGill University Health Centre (MUHC), ...
... significant differences between new and old red blood cells ... and effective way to monitor the quality of blood ... in banks continues to age, resulting in biomaterials leaking ... cell properties and function. There have been concerns ...
... Reinberg HealthDay Reporter , THURSDAY, May 19 (HealthDay ... an road accident has been able to stand up by ... steps on a treadmill, thanks to electrical stimulation of his ... cord stimulation -- mimics signals the brain normally sends to ...
... Reporter , THURSDAY, May 19 (HealthDay News) -- The U.S. ... drug Avandia will no longer be sold at retail pharmacies ... to patients. According to the new rules, which will ... be available to patients who,ve been safely using the ...
... May 19 (HealthDay News) -- Hispanic women who suffer ... a fivefold increased risk of postpartum depression, U.S. researchers ... is a stronger predictor of postpartum depression than prenatal ... risk factor. The study of 210 Hispanic women ...
... The Children,s Health Insurance Program Reauthorization Act (CHIPRA) ... quality measures to be identified for voluntary use by ... which together cover almost 40 million American children and ... official journal of the American Pediatric Association, noted authorities ...
Cached Medicine News:Health News:Enlarged prostate: Study demonstrates immediate and long-term benefits of laser treatment 2Health News:Research provides insight into quality of stored blood used for transfusions 2Health News:Research provides insight into quality of stored blood used for transfusions 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 2Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 4Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 2Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 4Health News:Important info about CHIPRA core set of recommended health care quality measures released 5
(Date:5/28/2015)... --  Clementia Pharmaceuticals, Inc. today announced that ... (Part B) of its natural history study in ... severely disabling congenital myopathy characterized by painful, recurrent ... in the formation of new, abnormal (heterotopic) bone ... The multi-center, non-interventional, two-part longitudinal study is designed ...
(Date:5/28/2015)... SAN DIEGO , May 28, 2015 ... immuno-oncology drug development company, announced today that its President ... present at the LD Micro Invitational Investor Conference ... Bel Air, California on June ... corporate update including highlights from the significant progress made ...
(Date:5/28/2015)... IRVING, Texas , May 28, 2015 /PRNewswire/ ... on fulfilling the promise of precision medicine, today ... cohort studies that demonstrate the utility of Caris ... service, in characterizing mechanisms of drug resistance and ... presented May 31 in poster sessions at the ...
Breaking Medicine Technology:Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 2Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 2MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 2Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 3Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 5
... Va. , Feb. 3 CEL-SCI Corporation ... Officer, will be presenting at the 2010 BIO CEO & Investor ... take place February 8-9 at the Waldorf=Astoria in ... Tuesday, February 9th , at 1:30 p.m. EST .  The ...
... , Feb. 3 Repligen Corporation (Nasdaq: RGEN ... from the United States Patent and Trademark Office for a patent ... structure to the commercial form of Protein A from Staphylococcus ... the world,s approved monoclonal antibodies . The patent, which ...
Cached Medicine Technology:CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference 2Repligen Receives Notice of Allowance for Recombinant Protein A Patent 2Repligen Receives Notice of Allowance for Recombinant Protein A Patent 3
TOX/See is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
... 350 Chemistry System offers easy operation, maintenance, and ... STAT, or back-up to the powerful VITROS 5,1 ... the job done right the first time. Its ... are efficient, dependable, and easy-to-use. The VITROS 350 ...
Medicine Products: